Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i&g...

Full description

Bibliographic Details
Main Authors: Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceuticals
Subjects:
<i>ALK</i>-positive disease
<i>ROS1</i>-positive disease
ALK tyrosine kinase inhibitor treatment
sequential treatment
lorlatinib
Online Access:https://www.mdpi.com/1424-8247/13/11/371

Internet

https://www.mdpi.com/1424-8247/13/11/371

Similar Items